|
Data sources used in model parameterization, calibration, and performance evaluation |
|
| Modeling Step |
Sources |
|
|
|
| Parameterization |
HPV infection rates |
| Primary Articles: [23-27] |
|
| Reviews: [14,20,21] |
|
| Progression rates to/within CIN |
|
| Primary Articles: [28-37] |
|
| Reviews: [14,20,21,38,39] |
|
| Regression rates from CIN and HPV clearance rates |
|
| Primary Articles: [37,40,41] |
|
| Reviews: [14,20,21,39] |
|
| Progression rates to/within cancer and cancer detection |
|
| Reviews: [14,20,21,42] |
|
| All-cause and cancer mortality rates |
|
| Reviews: [14,42,44] |
|
|
|
|
| Calibration |
Age-specific cervical cancer incidence |
| [43] |
|
| Cumulative cervical cancer incidence |
|
| [43,44] |
|
| Age-specific prevalence of high-risk and low-risk HPV |
|
| [45-61] |
|
| Age-specific prevalence of CIN1 and CIN2,3 |
|
| [45,47,50,62-71] |
|
| HPV type distribution by CIN/cancer status |
|
| Primary Articles: [58,72-90] |
|
| Review: [91-94] |
|
| Type-specific duration of HPV infections in younger and older women |
|
| [41] |
|
|
|
|
| Evaluation* |
Age-specific high-risk HPV prevalence and age-specific HSIL+ cytology prevalence |
| [95] |
|
| Proportion of CIN1 and CIN2,3 that are HPV-16 and HPV-18 or other high-risk HPV infected |
|
| [96] |
|
| Screening reduction in age-specific cancer incidence rates and cancer stage at detection |
|
| [43,97] |
|
|
* Screening patterns used in model evaluation: [98-102] | |
Goldhaber-Fiebert et al. Population Health Metrics 2007 5:11 doi:10.1186/1478-7954-5-11 |
|